Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C

Rationale for RAS mutation-tailored therapies

(2017) Steven K Montalvo et al.   Future Oncology

Intratumor heterogeneity: predicting and preventing therapeutic resistance

(2016) Demosthenes E Ziogas et al.   Biomarkers in Medicine

Selective Targeting of the KRAS G12C Mutant: Kicking KRAS When It’s Down

(2016) G. Aaron Hobbs et al.   CANCER CELL

Darwinian Dynamics of Intratumoral Heterogeneity: Not Solely Random Mutations but Also Variable Environmental Selection Forces

(2016) M. C. Lloyd et al.   CANCER RESEARCH

Covalent targeting of acquired cysteines in cancer

(2016) Marieke Visscher et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Recent advances in cancer drug discovery targeting RAS

(2016) Candice Y. Wilson et al.   DRUG DISCOVERY TODAY

The implications of small stem cell niche sizes and the distribution of fitness effects of new mutations in aging and tumorigenesis

(2016) Vincent L. Cannataro et al.   Evolutionary Applications

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma

(2016) Daisuke Hashimoto et al.   PANCREAS

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

(2016) P. Lito et al.   SCIENCE

Covalent Guanosine Mimetic Inhibitors of G12C KRAS

(2016) Yuan Xiong et al.   ACS Medicinal Chemistry Letters

Progress on Covalent Inhibition of KRASG12C

(2016) K. D. Westover et al.   Cancer Discovery

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

(2016) M. P. Patricelli et al.   Cancer Discovery

Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution

(2015) Nicholas McGranahan et al.   CANCER CELL

KRAS as a Therapeutic Target

(2015) F. McCormick   CLINICAL CANCER RESEARCH

Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?

(2015) A. D. Cox et al.   CLINICAL CANCER RESEARCH

Improving Prospects for Targeting RAS

(2015) Harshabad Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

The influence of subclonal resistance mutations on targeted cancer therapy

(2015) Michael W. Schmitt et al.   Nature Reviews Clinical Oncology

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

(2015) Lihua Huang et al.   Acta Pharmaceutica Sinica B

Oncogenic KRAS signalling in pancreatic cancer

(2014) S Eser et al.   BRITISH JOURNAL OF CANCER

MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung

(2014) H.-U. Schildhaus et al.   CLINICAL CANCER RESEARCH

Su1894 Exome Sequencing of Formalin Fixed Paraffin Embedded Pancreatic Ductal Adenocarcinoma Samples Expands Mutational Landscape and Identifies Hypermutator Phenotype

(2014) Silvia Vilarinho et al.   GASTROENTEROLOGY

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

(2014) Benjamin Izar et al.   Journal of Thoracic Oncology

KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma

(2014) Ernest Nadal et al.   Journal of Thoracic Oncology

Tumour heterogeneity and the evolution of polyclonal drug resistance

(2014) Rebecca A. Burrell et al.   Molecular Oncology

Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery

(2014) Cheng-Qiong Mao et al.   MOLECULAR THERAPY

Comprehensive molecular profiling of lung adenocarcinoma

(2014) Eric A. Collisson et al.   NATURE

Discovery and saturation analysis of cancer genes across 21 tumour types

(2014) Michael S. Lawrence et al.   NATURE

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

(2014) J. C. Hunter et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer

(2013) D. Tougeron et al.   ANNALS OF ONCOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

KRASMutation: Should We Test for It, and Does It Matter?

(2013) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

(2013) Jonathan M. Ostrem et al.   NATURE

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

The causes and consequences of genetic heterogeneity in cancer evolution

(2013) Rebecca A. Burrell et al.   NATURE

In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction

(2013) F. Shima et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer

(2013) Ondrej Fiala et al.   Cancer Genetics

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

A Comprehensive Survey of Ras Mutations in Cancer

(2012) I. A. Prior et al.   CANCER RESEARCH

Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer

(2012) Winfried H. Alsdorf et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation

(2012) Yoshihiko Fujita et al.   Journal of Thoracic Oncology

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

(2012) Sandra Misale et al.   NATURE

Comprehensive molecular characterization of human colon and rectal cancer

(2012)   NATURE

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

(2012) K. Ohashi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

(2010) Kenichi Suda et al.   Journal of Thoracic Oncology

Cigarette smoking and K-ras mutations in pancreas, lung and colorectal adenocarcinomas: Etiopathogenic similarities, differences and paradoxes

(2009) Miquel Porta et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA